Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

FDA new drug approvals in Q1 2022

  1. Lisa Urquhart

    1. Evaluate Vantage, London, UK.

    View author publications

    You can also search for this author in PubMed  Google Scholar

With the first quarter of 2022 now in the rear-view mirror, the FDA has approved 10 new drugs (Table 1), 4 short of the total this time last year. The decline might add fuel to speculation that the agency is showing more rigour around authorizations following the controversy surrounding Alzheimer’s drug Aduhelm (aducanumab). But despite what looks like a rise in complete response letters, many for manufacturing issues, it is too early in the year to give a clear steer in which direction the agency might be going under the leadership of newly elected commissioner Robert Califf.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 21, 329 (2022)

doi: https://doi.org/10.1038/d41573-022-00063-9

Updates & Corrections

  • Correction 20 April 2022: Suvorexant and and lemborexant were described as orexin receptor agonists rather than antagonists, and this has been corrected.

Competing Interests

The author declares no competing interests.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links